



Declaration of Interests

INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically; a copy of the form should be uploaded to the [EU PAS Register](#).

For ENCePP Seal studies only: the completed form is to be transmitted to the ENCePP Secretariat by email.

SECTION 1: PERSONAL DETAILS

First Name:

Last Name:

Organisation / Research Centre :

Country:

Contact e-mail Address:

Study Reference Number: EUPAS

Are you the (Primary) Lead Investigator of the above study? No Yes

Are you an investigator/researcher contributing to the above study No Yes

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY

In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered.

2.1 Employment

No Yes

Employment in a pharmaceutical company during past 3 years of study application?

Pharmaceutical company includes supply or service companies which contribute to research, development, production and maintenance of a medicinal product. Employment relates to salaries currently being directly paid to you by a pharmaceutical company.

2.2 Financial Interest

No Yes

Financial interests in the capital of a pharmaceutical company?

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pensions schemes that are not exclusively based on the pharmaceutical sector.

2.3 Patent

No Yes

Patent for a medicinal product?

Relates to a patent for a medicinal product currently owned by either you as individual or your organisation/ research centre, and you as individual are the beneficiary.

2.4 Consultancy

No Yes

Consultancy for a pharmaceutical company during the past 3 years of study application?

Consultancy refers to provision of advice or services to a pharmaceutical company excluding the concerned study and including but not limited to reviewing activities, data monitoring, statistical analysis, end point committees, regardless of contractual arrangements or any form of remuneration such as consulting fees or honoraria.

Note that conference/seminar attendance is not considered a consultancy but should be indicated if subject to fee or honorarium.

Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid:

Period: Current Past

From Month: From Year:

Name of Pharmaceutical Company:

Type of consultancy:

Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid:

Period: Current Past

From Month: From Year: To Month: To Year:

Name of Pharmaceutical Company:

Type of consultancy:

Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid:

Period: Current Past

From Month: From Year: To Month: To Year:

Name of Pharmaceutical Company:

Type of consultancy:

Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid:

Period: Current Past

From Month: From Year: To Month: To Year:

Name of Pharmaceutical Company:

Type of consultancy:

2.5 Strategic Advisory Role

No Yes

Strategic Advisory role on activities of a pharmaceutical company during the past 3 years of study application?

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

2.6 Grant / Funding

No Yes

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

Please specify the pharmaceutical company:

Name of Pharmaceutical Company	Comments
Aptalis	Drug utilisation study, safety and pharmacokinetic study of Pylera® in real-life
AstraZeneca	Benefit-risk of antiplatelet agents during secondary prevention of acute coronary syndrome in France
AstraZeneca	Health outcomes, resource use, costs in patients with stable coronary artery disease in France
AstraZeneca	Assessment of the high risk and unmet need in patients with coronary artery disease and type 2 diabetes in France
Bayer	Benefit-risk of arterial thrombotic prevention with rivaroxaban for atrial fibrillation in France
Biogen France	Effectiveness of Tecfidera® in multiple sclerosis in France
Biogen USA	Multiple sclerosis natural history study in France
BMS	Benefit-risk of antithrombotic treatments after orthopedic surgery in France
Boehringer	Benefit-risk of anticoagulants in nonvalvular atrial fibrillation in France
Janssen Cilag	Therapeutic strategy in metastatic castration-resistant prostate cancer in France
Janssen France	Assessment of the treatment-resistant depression in France
Lundbeck	Assessment of Selincro® in real-life
Merck Serono	Assessment of targeted therapies in patients with colorectal cancer treated with Erbitux® in first line treatment
Novartis	Post inscription studies of ranibizumab for visual impairment due to diabetic macular edema and retinal vein occlusion
Novartis	Assessment of the inhalation systems handling in patients with COPD in real-life
Novartis Pharma AG	A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive and/or BCR-ABL positive CML in chronic
Pierre Fabre	Observational cohort study of myocardial infarction with long-term follow-up in France
Sanofi-Aventis	Assessment of cabazitaxel in real-life
Stallergenes	Assessment of Oralair® in real-life
RTI(s)	Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions

SECTION 3: ANY OTHER INTERESTS

No Yes

In this section you should declare any other interests of commercial, financial, institutional or personal nature to be made known to the public.*

Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family? (*see definition in Annex 1 of ENCePP Code of Conduct)

Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.

Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly complete and upload a new Declaration of Interests detailing the changes.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the [EU PAS Register](#).

FULL NAME:

Patrick Blin

Date:

17/01/2019

[Submit Form by Email](#)

